BIO Asia–Taiwan 2023 亞洲生技大會

BIO Asia–Taiwan 2023 亞洲生技大會

論壇議程總覽

2023 亞洲生技論壇

​​

BIO Asia–Taiwan 2023
Conference Agenda 

Date July 26-28, 2023

Venue July 26 TaiNEX2 + Online event platform
July 27-28 TaiNEX1 + Online event platform

Day 1 - Wednesday, July 26
Day 2 - Thursday, July 27
Day 3 - Friday, July 28

09:00 – 10:40

Session 1 (Plenary) – Global Biotech Development
701EF, 7F, TaiNEX2

Novel medical technologies and drug platforms such as mRNA and lipid nanoparticles are revolutionizing healthcare, with applications in such critical areas as cancer treatment, rare diseases, and novel vaccines. We are honored to have join us today three recipients of the international Tang Prize in Biopharmaceutical Science, awarded for their role in developing mRNA vaccines, to examine what the future holds for these exciting new technologies. Join us for a thought-provoking and informative session on the cutting edge of drug development technologies.

09:00 – 10:30 Session 1 (Plenary) – Global Biotech Development
09:00 – 09:25

Conference Opening

Welcome
Johnsee Lee, Chairman of BIO Asia–Taiwan 2023
Chung-Hsiun Wu, Chairman, Taiwan Bio Industry Organization
Susanna Ling, Vice President, Industry Partnerships and Programs, Biotechnology Innovation Organization (BIO)


VIP Remarks

Yi-Juang Chern, Deputy Minister, National Science and Technology Council

09:25 – 09:45 Session Chair
Chung-Hsiun Wu, Chairman, Taiwan Bio Industry Organization

Impact of Key Policy Changing on Biopharma Industry

John A. Murphy, III, Chief Policy Officer, Deputy Counsel, Healthcare, Biotechnology Innovation Organization (BIO)

09:45 – 10:00 Design of Lipid Nanoparticles that Enable Gene Therapies

Pieter Cullis, Professor, University of British Columbia, 2022 Tang Prize Laureate

10:00 – 10:15 Developing mRNA for Therapy

Katalin Karikó, Professor of University of Pennsylvania and senior vice president of BioNTech RNA Pharmaceuticals, 2022 Tang Prize Laureate

10:15 – 10:30 2023 Health Trends

Sam Wilson, SVP and Head of APAC, Deployment Solutions, Syneos Health

10:30 – 10:40 Break

10:40 – 12:05

Session 2 (Plenary) – Global Biotech Development
701EF, 7F, TaiNEX2

The Asia Pacific region has become a hotbed of biotech investment. This session will explore the latest trends and opportunities in this space, with a special focus on Taiwan. Hear from industry leaders on the factors driving investment in the region, the challenges and opportunities for startups, and the outlook for future growth. We’ll also examine Asia’s role as a major clinical trials hub, and the latest innovations and best practices for conducting efficient and effective trials. Join our expert speakers as they examine the fast-evolving regulatory landscape, the impact of digital technologies, and the potential for new approaches to improve patient outcomes.

10:40 – 12:05 Session 2 (Plenary) – Global Biotech Development
10:40 – 10:55 Growth Opportunities in Precision Health: Moving from Sickcare to Healthcare

Unmesh Lal, Director, Healthcare & Life Sciences, Frost & Sullivan

10:55 – 11:10 Nucleoside-modified mRNA-LNP Therapeutics

Drew Weissman, Professor, University of Pennsylvania, 2022 Tang Prize Laureate

11:10 – 11:25 Global Trends and Future Opportunities in Pharma

Aurelio Arias, Director, Global Thought Leadership, IQVIA

11:25 – 11:40 Accelerate Digital Tech Transfer from Research to Development to Manufacturing Adhering Quality

Basha Kodidela, Senior Manager – Technical Sales APAC, BIOVIA

11:40 – 11:55 Biotech & Pharma Supply (incl. CDMO) – Trends, Dynamics and Implications

Jens Neumann, Partner, Pharmaceutical and Life Sciences Operations Strategy Leader in Europe, PwC Strategy& (Germany) GmbH

11:55 – 12:05 Closing

Chung-Hsiun Wu, Chairman, Taiwan Bio Industry Organization

12:20 – 13:50

Session 3 – Gap Filling of Health Investment for a Brighter Future
701EF, 7F, TaiNEX2

The biotech industry is increasingly global in scope, with international collaboration considered an essential element for success. This session will delve into the strategies and best practices for collaboration between multinational companies and local partners, and examine the challenges and opportunities that arise from cross-border partnerships. Gain an understanding of how multinational companies can support Taiwan's precision healthcare development goals, including the sharing of resources, expertise, and infrastructure. We’ll also explore the clinical trial ecosystem, focusing on the latest trends and innovations in trial design and implementation, and highlighting the importance of collaboration between academia, industry, and regulatory bodies.

12:20 – 13:50 Session 3 – Gap Filling of Health Investment for a Brighter Future
12:20 – 12:25 Welcome Remarks

Johnsee Lee, Chairman of BIO Asia–Taiwan 2023

12:25 – 12:30 Opening Remarks

Hidehito Katsuma, President, IRPMA; President, Eli Lilly Taiwan

12:30 – 12:40 International Biomedical Innovation Industry Ecosystem Trend
Fong, Pei-Chieh, VP Medical International, AstraZeneca
12:40 – 12:50 Global Trends in Digital Healthcare

Francois Barbe, Head of Digital Healthcare, Sanofi Hong Kong & Taiwan

12:50 – 13:00 Taiwan's Biomedical Industry in Line with International Standards and Competitive Advantages

Chung-Hsiun Wu, Chairman, Taiwan Bio Industry Organization

13:00 – 13:45 Panel Discussion

Moderator:
Johnsee Lee, Chairman of BIO Asia–Taiwan 2023
Panelists:

13:45 – 13:50 Closing Remarks

Kelly Lam, General Manager, General Medicines Business Unit, Sanofi Hong Kong & Taiwan

14:00 – 15:30

Session 4 – How to Bring New Drugs to Global Markets?
701EF, 7F, TaiNEX2

This session will focus on the key factors to successfully launching new products onto world markets; technology, utilizing AI, for example; reimbursement, understanding both policy and current practices; patient diversity; and economics, including tapping investment and capital markets. Speakers will share experience and insights on navigating regulatory environments, managing clinical trials, and addressing the needs of patients and stakeholders. The session will also highlight the latest innovations in drug development, such as precision medicine and digital health technologies, and the potential for these approaches to improve patient outcomes and streamline the drug development process. Attendees can expect to gain valuable insights into what it takes for successful global drug development.

14:00 – 15:30 Session 4 – How to Bring New Drugs to Global Markets?
14:00 – 14:05 Opening Remarks
14:05 – 15:30 Panel Discussion

Moderator:
John Tsai, Executive Partner, Syncona; Former President Global Drug Development & CMO of Novartis; Blueprint Medicines Board member
Panelists:

15:40 – 17:10

Session 5 – Invest for 2024 and Beyond
701EF, 7F, TaiNEX2

Despite the challenging capital market environment of 2022, the Asian biotech and healthcare sector demonstrated resilience and even growth, significantly outperforming the main indices in markets across the greater Asian region. However, in a cautious investment environment, biotech companies must look to alternative funding sources to support research-intensive programs. This session has assembled top Asian investment bankers and financial professionals from leading institutions to discuss capital funding strategies and future opportunities and challenges for the biotech industry across Asia. Speakers include senior representatives from Goldman Sachs, Citigroup, and NASDAQ. Join us for an enlightening discussion on biotech investing for 2024 and beyond.

15:40 – 17:10 Session 5 – Invest for 2024 and Beyond
15:40 – 15:45 Opening Remarks

Joseph Chou, Chairman and CEO, PwC Taiwan

15:45 – 17:10 Panel Discussion

Moderator
Peter Kurz, Chief Strategy Officer, QIC International
Panelists

09:00 – 10:30

Session 6 – BIO Asia–Taiwan 2023 Opening & Award Ceremony (By Invitation Only)
4F, TaiNEX1

09:00 – 10:30 Session 6 – BIO Asia–Taiwan 2023 Opening & Award Ceremony (By Invitation Only)
09:00 – 09:30 Admission
09:30 – 09:35 Introducing Honorable Guests
09:35 – 09:37 Welcoming Remarks

Johnsee Lee, Chairman of BIO Asia–Taiwan 2023

09:37 – 09:43 Opening Speech
09:43 – 09:46 VIP Remarks

Rachel King, CEO, Biotechnology Innovation Organization (BIO)

09:46 – 10:05 2023 Taiwan BIO Awards Ceremony
10:05 – 10:15 Ribbon-cutting Ceremony
10:15 Adjourn

10:40 – 12:10

Session 7 – Sharing Biotech Successes-Taiwan BIO Awardee Showcase
401, 4F, TaiNEX1

10:40 – 12:10 Session 7 – Sharing Biotech Successes-Taiwan BIO Awardee Showcase
10:40 – 10:45 Opening & Group Photo
10:45 – 12:10 Sharing the Experience of Biotech Success
2023 Taiwan BIO Awards Winners:

- Outstanding Company of the Year

- Emerging Company of the Year

- Innovation of the Year

12:20 – 13:50

Session 8 – Crossing Borders, Establishing a Global Biotech Ecosystem
401, 4F, TaiNEX1

With the theme of " Crossing Borders, Establishing a Global Biotech Ecosystem", this luncheon aims to explore how to establish a comprehensive innovative environment that helps foster innovation and accelerate cross-disciplinary cooperation. At the same time, this environment will also facilitate the latest global R&D trends and connect global supply chains to support the breakthrough of emerging technologies. For the biotechnology and medical industries, which are closely related to the welfare of human beings, immediate actions to connect innovation and CDMO resources should be implemented.
At this session, international start-ups and CDMO supportive networks, including AIT, Johnson & Johnson, New Deantronics, Ernst & Young, ITRI and others, will be invited to share their successful experiences in their ventures as well as their global supply chain cooperation cases. It is hoped that this event initiates constructive conversations and brings more diversified perspectives to all parties involved.

12:20 – 13:50 Session 8 – Crossing Borders, Establishing a Global Biotech Ecosystem
12:20 – 12:30 Welcoming Remarks
Representative from MOEA, Taiwan
Eric Y. Chuang, General Director, Biomedical Technology and Device Research Laboratories, ITRI

Opening Remarks
Jeffrey Dutton, Commercial Officer, American Institute in Taiwan (AIT)
12:30 – 12:45 Enhancing Taiwan's Biomedical R&D Capacity Through International Collaboration

Eric Y. Chuang, General Director, Biomedical Technology and Device Research Laboratories(BDL), ITRI

12:45 – 13:15 Innovation: the Essential Ingredients of Competitiveness
Sipra Bond, Vice President, Supply Chain, Ethicon Inc., Johnson & Johnson
Arthur Stephen, Vice President, EndoMechanical & Energy R&D, Ethicon Inc., Johnson & Johnson
13:15 – 13:50

Panel Discussion: Crossing Borders, Establishing a Global Biotech Ecosystem

Moderator:

Chii-Wann Lin, Senior Research Consultant, Biomedical Technology and Device Research Laboratories (BDL), ITRI

Panelists:

14:00 – 15:30

Session 9 – New Asian Age
401, 4F, TaiNEX1

As global regulatory authorities are winding down the path to expedited reviews for coronavirus-related subjects, life science companies are urged to follow their traditional regulatory paths to market. Without a doubt, uncertainty remains elevated and creates a dramatic impact on global economies. Life science companies must continue to differentiate themselves by formulating strategies with broader and more rigorous approaches to stay agile and create value. Across biotech and healthcare industries, Asia is becoming critically important to the global life science ecosystems. Taiwan sits right in the epicenter of this Asia ecosystem and establishes itself as a trusted hub for biotechnology. Taiwan offers significant advantages in life science R&D such as high-quality medical data, a deep well of scientific and biomedical talents for conducting clinical trials, drug discovery, advanced diagnostics, and a booming life science capital market.

14:00 – 15:30 Session 9 – New Asian Age
14:00 – 14:10 Opening Remarks

Jerome Shen, General Partner, Bio Fund, Taiwania Capital Management Corp.

14:10 – 14:30 New Modalities in Biotech: Now and Tomorrow

Roger J. Pomerantz, Chairman of the Board, Viracta Therapeutics

14:30 – 14:50 Harnessing Strategic Alliances to Thrive During Turbulent Times

Hiroshi Yamamoto, Managing Director, Head of Asia, Locust Walk; Founder & CEO, Eighty-Eighty Therapeutics

14:50 – 15:25 Panel Discussion: Navigating Cross-border Collaborations in Drug Development: Lessons Learned and Future Opportunities

Moderator:
Victoria Wang, Principal, Bio Fund, Taiwania Capital Management Corp.
Panelists:

15:25 – 15:30 Closing Remarks

Michael Huang, Managing Partner, Bio Fund, Taiwania Capital Management Corp.

15:40 – 17:10

Session 10 – Clinical Impacts of Precision Health
401, 4F, TaiNEX1

This session will explore the latest developments and innovations at the intersection of precision health and clinical medicine. Examine the latest diagnostic tools and technologies driving the uptake of precision health, including next-generation sequencing for identifying treatment targets. Participants can expect to gain a deeper understanding of the ways in which precision health is transforming clinical practice and healthcare overall, and learn about the latest developments in moving from trial to treatment. This is a must-attend session for anyone looking to stay at the forefront of the rapidly evolving precision health landscape.

15:40–17:10 Session 10 – Clinical Impacts of Precision Health
15:40-15:45 Opening Remarks

Huey-Kang Sytwu, President, National Health Research Institutes

Moderator:

Shih-Feng Tsai, Distinguished Investigator, National Health Research Institutes

15:45-16:00 Creating a Vibrant Ecosystem for Precision Medicine in Asia Pacific

Helen Chen, Global Sector Co-Head, Healthcare and Life Sciences Greater China Managing Partner, L.E.K. Consulting

16:00-16:15 GUARDIAN: Genomic Uniform-screening Against Rare Diseases in All Newborns
Wendy Chung, Chief of the Department of Pediatrics, Boston Children’s Hospital & Harvard Medical School
16:15-16:30 Implementing a Quality Healthcare Genomic Medicine Service

Sandi Deans, Deputy Director, Genomics Unit, NHS England; Director, Genomics Quality Assessment (GenQA) 

16:30-16:45 HTA of Precision Medicine Diagnostics in Korea

Jeonghoon Ahn, Professor, Department of Health Convergence, Ewha Womans University

16:45-17:10 Panel Discussion

Moderator:
Chris Tsai, Chairman, Precision Medicine Industry Association of Taiwan
Panelists:

09:00 – 10:30

Session 11 – Cell and Gene Therapies with Novel Enabling Platform
401, 4F, TaiNEX1

This session will showcase the latest novel biotech platforms from around the world. Speakers from both academia and industry will explore the cutting-edge technologies and platforms that are changing the game, from next-generation gene editing tools to revolutionary new drug delivery systems. Attendees can expect to gain a deeper understanding of the latest developments in biotech research and innovation, and learn about the most promising new platforms. Stay ahead of the curve and explore the latest advances that are driving biotech research and innovation to new heights. Don’t miss out on this must-attend session!

09:00 – 10:30 Session 11 – Cell and Gene Therapies with Novel Enabling Platform
09:00 – 09:03 Opening Remarks

Han-Chung Wu, Director, Biomedical Translation Research Center (BioTReC), Academia Sinica, Taiwan

09:03 – 09:13 Frontier in Gene and Cell Therapies

John Tsai, Executive Partner, Syncona; Former President Global Drug Development & CMO of Novartis; Blueprint Medicines Board member

09:13 – 09:25 Gene Therapy at a Crossroad

Luk Vandenberghe, Associate Professor at Harvard Medical School & an Associate Member of the Broad Institute of Harvard & MIT. Founder, AKOUOS

09:25 – 09:40 First-in-Human Dose Selection for Cell and Gene Therapies 

Wen-Chyi Shyu, CEO, BRIM Biotechnology; Former Vice President, Head of Global Drug Metabolism and Pharmacokinetics, Takeda Pharmaceutical International Company

09:40 – 09:55 Opportunity of Proteomics-guided Precision Oncology

Yu-Ju Chen, Distinguished Research Fellow, Institute of Chemistry, Academia Sinica

09:55 – 10:10 The Perfect Storm of Challenges in Cell and Gene Therapy Clinical Development and Commercialization

Wei Wang, Corporate and Business Development Director, Cell and Gene Therapy, Syneos Health

10:10 – 10:28 Panel Discussion
Moderator:

Chia-Ning Shen, Researcher Fellow, Genomics Research Center, Academia Sinica, Taiwan
Panelists:

10:28 – 10:30 Closing Remarks

Han-Chung Wu, Director, Biomedical Translation Research Center (BioTReC), Academia Sinica, Taiwan

10:40 – 12:10

Session 12 – New Modality Development
401, 4F, TaiNEX1

Explore the latest and most promising new therapeutic modalities that are transforming healthcare today. Discover exciting new therapies as well as the latest drug development innovations; including gene and cell therapies, RNA-based therapies, and next-generation biologics. Learn from our panel of leading industry experts from Asia and around the world as they examine the latest trends, developments and future possibilities in therapeutics.

10:40 – 12:10 Session 12 – New Modality Development
10:40 – 10:45 Opening Remarks

Chung-Hsiun Wu,  Chairman, Taiwan Bio Industry Organization

10:45 – 11:05 CMC Strategy for siRNA Therapeutics

Lubomir Nechev, Senior Vice President CMC Development, Alnylam Pharmaceuticals

11:05 – 11:25 Adeno‐Associated Virus Production Platforms for Gene Therapy

Yvette Tang, Vice President of Drug Substance Technology, BioMarin Pharmaceutical

11:25 – 11:45 High Throughput Prediction of the Best Multi-Functional Molecules to Develop in the Clinic Through Preclinical Data Analysis

Ignacio Asial, Founder and CEO, DotBio

11:45 – 12:10 Panel Discussion

Moderator:
Chung-Hsiun Wu, CEO, Development Center for Biotechnology
Panelists:

12:20 – 13:50

Session 13 – Empowering Patient-Centric Digital Health
401, 4F, TaiNEX1

Digital health is a rapidly growing field with the potential to transform the way we approach healthcare. In this session, speakers will discuss the latest developments in digital health infrastructure development with a particular focus on Asia, and how these advancements are paving the way for a future of personalized, data-driven healthcare across the region. Understand the disruptive potential of the digital health revolution, and gain insights into the latest trends and emerging technologies that are shaping the industry. Whether you're a medical professional, investor, or simply interested in the future of healthcare in Asia and beyond, this session is for you.

12:20 – 13:50 Session 13 – Empowering Patient-Centric Digital Health
12:20 - 12:25 Opening Remarks

Liang-Gee Chen, Chairman, Taiwan Digital Health Industry Development Association

12:25 - 12:40 Building a Digital Health Ecosystem

Jared Josleyn, Head of General Medicines Digital Health Care, Sanofi

12:40 - 12:55 Digital Health Innovation and Development from the Perspectives of the National Health Insurance

Chung-Liang Shih, Director General, National Health Insurance Administration, Ministry of Health and Welfare

12:55 - 13:10 Digital Healthcare in APAC – A Sandbox for Patient-Centric and Commercial Innovations

David Xie, Partner, Deloitte Consulting

13:10 - 13:25 Reimbursement as Enabler to Innovation: Mindset and Framework to Overcome Challenges of the Healthcare Ecosystem

Josh Makower, Director, Stanford Byers Center for Biodesign

13:25 - 13:50 Panel Discussion

Moderator:
Liang-Gee Chen, Chairman, Taiwan Digital Health Industry Development Association
Panelists:

14:00 – 15:30

Session 14 – Robust Manufacturing for Cell and Biologics
401, 4F, TaiNEX1

With Asia a fast-growing global CDMO hub, we’ll deep dive into the latest trends, opportunities, and challenges facing the biomedical supply chain and contract manufacturing industries. Expert speakers will share their knowledge and experience in navigating complex regulatory landscapes, improving manufacturing processes, and enhancing supply chain resilience and agility. Whether you're a biotech industry professional, a healthcare provider, or an investor, this session offers a unique opportunity to stay up-to-date on the latest developments and best practices in supply chain and bio-manufacturing.

14:00–15:30 Session 14 – Robust Manufacturing for Cell and Biologics
14:00-14:05 Opening Remarks

Bobby Sheng, Chairman & CEO, Bora Pharmaceuticals & Bora Biologics
Lee-Cheng Liu, Dr. Sci. Eng., Founder, Chairman and President of EirGenix

14:05-14:45 Development and Manufacturing of Highly Engineered MAbs

Moderator:
Robert Gustines, SVP Commercial Operations, Bora Biologics 
Panelists:

14:45-14:50 Break
14:50-15:30 Cell and Gene Therapy

Moderator:
Lee-Cheng Liu, Dr. Sci. Eng., Founder, Chairman and President of EirGenix
Panelists:

15:40 – 17:10

Session 15 – Biodesign for the Future of MedTech
401, 4F, TaiNEX1

Don't miss this exciting session on the future of medtech! Our expert speakers will explore the latest health-tech innovations, and discuss strategies for connecting with innovators from across the APAC community. Gain valuable insights into emerging medical technology trends and opportunities, from the latest breakthroughs in devices to cutting-edge digital health solutions. With a focus on collaboration and cross-border partnerships, this session offers a unique opportunity to connect with industry leaders and explore new pathways to success in this dynamic and rapidly evolving industry. Get ready to be inspired, empowered, and energized as you explore the limitless potential of the medtech revolution!

15:40–17:10 Session 15 – Biodesign for the Future of MedTech
15:40–15:45 Opening Remarks

Chien-Huang Lin, President, Taipei Medical University

15:45–16:00 Stanford Biodesign: The Origin and Future of Need-Driven Health Technology Innovation

Josh Makower, Director, Stanford Byers Center for Biodesign

16:00–16:15 APAC Region: a Powerful Community of Innovators for the Health of the World

Anurag Mairal, Director, Global Outreach Programs at Stanford Byers Center for Biodesign

16:15–17:10 Panel Discussion

Moderator:
Jiunn-Horng Kang, Dean, College of Biomedical Engineering, Taipei Medical University

Panelists: